- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Natco Pharma Q2 Net Profit Plunges 61% to Rs 203 Crore as Revenue Falls 29%

New Delhi: Natco Pharma on Friday posted a 60.8 per cent decline in consolidated net profit to Rs 202.6 crore during the September quarter, weighed down by a fall in revenues.
The pharma company had reported a net profit of Rs 517.9 crore in the corresponding period of the preceding fiscal.
Its revenue from operations declined to Rs 967.3 crore in the second quarter of FY27 from Rs 1,363 crore a year ago, the company said in a regulatory filing.
Total expenses stood at Rs 776.2 crore, down from Rs 849.3 crore a year ago, it said.
During the quarter, Natco acquired an additional 13.25 per cent stake in Adcock Ingram Holding Ltd.
In the first half of the current fiscal (H1 FY27), Natco Pharma posted a 59 per cent decline in net profit to Rs 409.1 crore from Rs 998.2 crore in the April-September period of the preceding financial year.
The company's board of directors also approved an interim dividend of Rs 1.25 per equity share of Rs 2 each during the quarter under review.
Shares of Natco Pharma closed 0.22 per cent lower at Rs 807 apiece on the BSE.
Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

